Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy

Fluids Barriers CNS. 2019 Sep 5;16(1):28. doi: 10.1186/s12987-019-0148-3.

Abstract

Progressive multifocal leukoencephalopathy (PML), caused by infection with John Cunningham polyoma virus (JCPyV) in immune-compromised patients, is a serious demyelinating disease of the central nervous system. This disease often leads to major neurological impairments and consecutive disability. No effective treatment for PML has been found as yet. As JCPyV-PCR of the cerebrospinal fluid (CSF) may be negative in some cases, a reliable diagnosis might prove to be difficult as well. So far, two case reports suggested CSF-tau to be a promising biomarker for PML. Our study included 10 patients with assured diagnosis of PML and varying underlying diseases. In all but one the CSF-tau concentration was normal. Our results indicate that CSF-tau is not an appropriate biomarker for PML.

Keywords: Biomarker; Cerebrospinal fluid; Immunosuppression; Progressive multifocal leukoencephalopathy; Tau-protein.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / cerebrospinal fluid
  • Female
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / cerebrospinal fluid*
  • Leukoencephalopathy, Progressive Multifocal / diagnosis*
  • Male
  • Middle Aged
  • tau Proteins / cerebrospinal fluid*

Substances

  • Biomarkers
  • MAPT protein, human
  • tau Proteins